For the quarter ending 2025-09-30, BTAI had $18,745K increase in cash & cash equivalents over the period. -$18,787K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -30,911 | -26,441 |
| Depreciation | 75 | 151 |
| Accretion of debt discount and amortization of financing costs | 440 | 743 |
| Change in fair value of derivative liabilities | -12,541 | 7,222 |
| Stock-based compensation expense | 581 | 1,736 |
| Payable-in-kind interest on credit agreement | 1 | 5,433 |
| Operating lease right-of-use assets | 82 | 160 |
| Accounts receivable | -17 | -114 |
| Inventory | -47 | -173 |
| Prepaid expenses, other current assets and other assets | 480 | -673 |
| Accounts payable, accrued expenses, due to related parties, and other current liabilities | -1,084 | 45 |
| Accrued interest | 0 | 0 |
| Operating lease liabilities | -96 | -183 |
| Net cash used in operating activities | -18,787 | -24,618 |
| Purchases of equipment and leasehold improvements | 0 | 0 |
| Net cash from investing activities | 0 | 0 |
| Proceeds from issuance of common stock and warrant | 38,234 | 14,146 |
| Offering costs for common stock and warrants issuance | 686 | 806 |
| Payment of employee tax obligations related to vesting restricted stock units | 16 | 1 |
| Net cash provided by financing activities | 37,532 | 13,339 |
| Net increase in cash, cash equivalents and restricted cash | 18,745 | -11,279 |
| Cash and cash equivalents at beginning of period | 29,854 | - |
| Cash and cash equivalents at end of period | 37,320 | - |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)